Nakanishi F, Mogi H, Sugiishi M, Sugiura I, Ogasawara T, Kinoshita T, Hoshino A
Gan To Kagaku Ryoho. 1986 Dec;13(12):3413-8.
Twenty-eight patients with advanced adenocarcinoma of the lung were treated with the combination chemotherapy "EACAM" consisting of cyclophosphamide (333 mg/m2 X 1), adriamycin (27 mg/m2 X 1), cisplatin (25 mg X 5), nimustine (33 mg/m2 X 1), and methotrexate (27 mg/m2 X 3). This regimen was repeated once every 4 or 5 weeks. One complete response (CR) and 10 partial responses (PR) were obtained in 27 evaluable patients and the response rate was 40.7%. The 50% survival time for all of the evaluable cases was 64 weeks. The 50% survival time for the responding patients (93 weeks) was significantly superior (p = 0.002) to that of the nonresponding patients (52 weeks). Alopecia, myelosuppression and mild G I trouble were observed, but these presented no obstacle to the continuation of the therapy. The combination chemotherapy "EACAM" is therefore considered to be a very effective and tolerable treatment for advanced adenocarcinoma of the lung, and can help in achieving our aim of prolonging the survival time of such patients.
28例晚期肺腺癌患者接受了由环磷酰胺（333mg/m²×1）、阿霉素（27mg/m²×1）、顺铂（25mg×5）、尼莫司汀（33mg/m²×1）和甲氨蝶呤（27mg/m²×3）组成的联合化疗方案“EACAM”。该方案每4或5周重复一次。27例可评估患者中获得1例完全缓解（CR）和10例部分缓解（PR），缓解率为40.7%。所有可评估病例的50%生存时间为64周。缓解患者的50%生存时间（93周）显著优于（p = 0.002）未缓解患者（52周）。观察到脱发、骨髓抑制和轻度胃肠道不适，但这些并未妨碍治疗的继续进行。因此，联合化疗方案“EACAM”被认为是治疗晚期肺腺癌非常有效且耐受性良好的方法，有助于实现延长此类患者生存时间的目标。
